Clinical Trials in Rare Disease: Challenges and Opportunities

被引:158
作者
Augustine, Erika F. [1 ]
Adams, Heather R. [1 ]
Mink, Jonathan W. [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
关键词
Batten disease; clinical trials; lysosomal storage disease; neuronal ceroid lipofuscinosis; rare disease; NEURONAL CEROID-LIPOFUSCINOSIS; ENZYME REPLACEMENT THERAPY; BONE-MARROW-TRANSPLANTATION; JUVENILE BATTEN-DISEASE; LIFE-LIMITING CONDITIONS; MOUSE MODEL; QUANTITATIVE DESCRIPTION; ANTIOXIDANT TREATMENT; LAMOTRIGINE THERAPY; GAUCHERS-DISEASE;
D O I
10.1177/0883073813495959
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The neuronal ceroid lipofuscinoses constitute one of many groups of rare childhood diseases for which disease-modifying treatments are nonexistent. Disease-specific barriers to therapeutic success include incomplete understanding of disease pathophysiology and limitations of treatments that cannot adequately cross the blood-brain barrier to access the central nervous system. Therapeutic development in the neuronal ceroid lipofuscinoses shares many challenges with other rare diseases, such as incomplete understanding of natural history to inform trial design, need for alternatives to the randomized controlled clinical trial, requirement for more sensitive outcome measures to quantify disease, limited access to resources required to mount a clinical trial (including funding), and difficulties of recruiting a small sample to participation. Solutions to these barriers will require multicenter collaboration, partnership with patient organizations, training a new generation of researchers interested in rare diseases, and leveraging existing resources.
引用
收藏
页码:1142 / 1150
页数:9
相关论文
共 76 条
[1]   Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis [J].
Åberg, L ;
Kirveskari, E ;
Santavuori, P .
EPILEPSIA, 1999, 40 (06) :796-799
[2]   Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis [J].
Aberg, L. ;
Talling, M. ;
Harkonen, T. ;
Lonnqvist, T. ;
Knip, M. ;
Alen, R. ;
Rantala, H. ;
Tyynela, J. .
NEUROLOGY, 2008, 70 (14) :1218-1220
[3]   Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL) [J].
Aberg, L ;
Heiskala, H ;
Vanhanen, SL ;
Himberg, JJ ;
Hosking, G ;
Yuen, A ;
Santavuori, P .
NEUROPEDIATRICS, 1997, 28 (01) :77-79
[4]   Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis [J].
Åberg, LE ;
Bäckman, M ;
Kirveskari, E ;
Santavuori, P .
EPILEPSIA, 2000, 41 (10) :1296-1302
[5]   A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis [J].
Åberg, LE ;
Rinne, JO ;
Rajantie, I ;
Santavuori, P .
NEUROLOGY, 2001, 56 (09) :1236-1239
[6]  
Adams HR, JNCLR13 NAT I NEUR D
[7]  
[Anonymous], 2010, NATURE, V466, P160
[8]  
Backman M L, 2001, Eur J Paediatr Neurol, V5 Suppl A, P163, DOI 10.1053/ejpn.2000.0455
[9]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[10]  
Bennett M J, 1988, Am J Med Genet Suppl, V5, P275